CTI BioPharma Corp. (NASDAQ:CTIC) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Wednesday.

Separately, Jefferies Group LLC began coverage on CTI BioPharma Corp. in a report on Tuesday, September 12th. They set a “buy” rating and a $7.50 price target on the stock.

Shares of CTI BioPharma Corp. (NASDAQ CTIC) traded down 1.22% on Wednesday, reaching $3.23. 113,983 shares of the company traded hands. The company’s market capitalization is $102.47 million. The firm’s 50 day moving average is $3.26 and its 200 day moving average is $3.62. CTI BioPharma Corp. has a one year low of $2.70 and a one year high of $6.48.

CTI BioPharma Corp. (NASDAQ:CTIC) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.63. The company had revenue of $22.23 million for the quarter. CTI BioPharma Corp. had a negative return on equity of 418.99% and a negative net margin of 136.76%. Analysts expect that CTI BioPharma Corp. will post ($1.26) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “ValuEngine Lowers CTI BioPharma Corp. (CTIC) to Strong Sell” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/11/valuengine-lowers-cti-biopharma-corp-ctic-to-strong-sell.html.

In related news, Director Richard L. Love sold 14,600 shares of CTI BioPharma Corp. stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $3.21, for a total value of $46,866.00. Following the transaction, the director now directly owns 84,318 shares of the company’s stock, valued at $270,660.78. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.08% of the stock is owned by insiders.

A hedge fund recently bought a new stake in CTI BioPharma Corp. stock. WASHINGTON TRUST Co bought a new position in shares of CTI BioPharma Corp. (NASDAQ:CTIC) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 31,400 shares of the biopharmaceutical company’s stock, valued at approximately $104,000. WASHINGTON TRUST Co owned 0.11% of CTI BioPharma Corp. as of its most recent SEC filing. Institutional investors and hedge funds own 42.87% of the company’s stock.

CTI BioPharma Corp. Company Profile

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.